SCHEMBL13005649

SCHEMBL13005649

CC(C)Cc1cccc(CN(CCN(C)C)Cc2ccccc2I)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CALM1 P0DP23 1/20 0.45
CAMKK2 Q96RR4 1/20 0.45
TSHR P16473 3/20 0.38
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
CETP P11597 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
SIGMAR1 Q99720 1/20 0.35
BCHE P06276 2/20 0.35
ACHE P22303 1/20 0.34
GRIN2D O15399 1/20 0.34
GRIN3B O60391 1/20 0.34
GRIN1 Q05586 1/20 0.34
GRIN2A Q12879 1/20 0.34
GRIN2B Q13224 1/20 0.34
GRIN2C Q14957 1/20 0.34
GRIN3A Q8TCU5 1/20 0.34
RECQL P46063 1/20 0.32
SLC6A4 P31645 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13005546 0.87 CALM1 (0.47) CALM1CAMKK2TSHRALDH1A1KDM4E
SCHEMBL13005713 0.86 CALM1 (0.46) CALM1CAMKK2TSHRALDH1A1KDM4E
SCHEMBL13061136 0.86 CALM1 (0.48) CALM1CAMKK2TSHRALDH1A1KDM4E
SCHEMBL13005440 0.85 CALM1 (0.59) CALM1CAMKK2TSHRALDH1A1KDM4E
SCHEMBL13005676 0.85 CALM1 (0.45) CALM1CAMKK2TSHRALDH1A1KDM4E
SCHEMBL13005661 0.85 CALM1 (0.45) CALM1CAMKK2TSHRALDH1A1KDM4E
SCHEMBL13005601 0.84 CYP2D6 (0.46) CALM1CAMKK2TSHRALDH1A1KDM4E
SCHEMBL13005498 0.83 CALM1 (0.46) CALM1CAMKK2TSHRALDH1A1KDM4E
SCHEMBL13005561 0.83 CALM1 (0.52) CALM1CAMKK2TSHRALDH1A1KDM4E
SCHEMBL13005715 0.82 CALM1 (0.43) CALM1CAMKK2TSHRALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851637-B2 Compounds and methods for inhibiting the interaction of BCL proteins with binding partners INFINITY PHARMACEUTICALS, INC. (US) 2010-12-14 US disclosed